SkinBioTherapeutics plc

SBTX

GB00BF33H870

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:11 2024-04-26 am EDT			5-day change	1st Jan Change
9.25 ^GBX	0.00%		0.00%	-39.34%

Apr. 05	SkinBioTherapeutics Gets Bond Conversion Notice from Macquarie	MT
Mar. 22	SkinBioTherapeutics half-year revenue jumps on UK-based sales	AN

SkinBioTherapeutics plc Provides Earnings Guidance for the Year Ending June 30, 2024

March 22, 2024 at 03:00 am EDT

SkinBioTherapeutics plc provided earnings guidance for the year ending June 30, 2024. The Group remains in line with management expectations for the full year to June 2024.

Latest news about SkinBioTherapeutics plc

SkinBioTherapeutics Gets Bond Conversion Notice from Macquarie	Apr. 05	MT
SkinBioTherapeutics half-year revenue jumps on UK-based sales	Mar. 22	AN
SkinBioTherapeutics plc Provides Earnings Guidance for the Year Ending June 30, 2024	Mar. 22	CI
SkinBioTherapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023	Mar. 22	CI
SkinBioTherapeutics' Chief Scientific Officer to Step Down	Mar. 18	MT
SkinBioTherapeutics Launches Project for Development of Wound Healing Technology	Mar. 18	MT
SkinBioTherapeutics announces research into wound healing bacterium	Mar. 18	AN
Cath O'Neill Confirms Intention to Stand Down as Chief Scientific Officer and Move to a Scientific Adviser Role at SkinBioTherapeutics plc	Mar. 18	CI
SkinBioTherapeutics plc Initiates a Research and Development Project with the University of Manchester	Mar. 18	CI
SkinBioTherapeutics Gets Bond Conversion Notice From Macquarie	Mar. 12	MT
Avacta plans fundraise to fund clinical development	Feb. 28	AN
Windward extends LSEG pact; Vinanz eyes DTC trading	Feb. 27	AN
SkinBioTherapeutics Reports ‘Very Positive’ Interim Data from Acne Food Supplement Study	Feb. 27	MT
SkinBioTherapeutics plc Announces Positive Interim Data from Consumer Participant Study for Acne	Feb. 27	CI
SkinBio's Dermatonics launches Once Heel Balm in Asia, ME and Africa	Feb. 20	AN
SkinBioTherapeutics Unit Plans Roll Out of Dry Foot Skin Treatment Balm	Feb. 20	MT
SkinBioTherapeutics up after successful year for Dermatonics	Feb. 06	AN
SkinBioTherapeutics completes Dermatonics purchase	Jan. 26	AN
SkinBioTherapeutics Finalizes Dermatonics Purchase; Shares Fall	Jan. 26	MT
SkinBioTherapeutics plc acquired Dermatonics Ltd.	Jan. 25	CI
SkinBioTherapeutics buys Dermatonics; in talks for 2nd deal	Jan. 25	AN
SkinBioTherapeutics Obtains GBP5 Million Convertible Bond Loan	Jan. 25	MT
SkinBioTherapeutics to Buy Skin Cream Brand Dermatonics	Jan. 25	MT
SkinBioTherapeutics plc agreed to acquire Dermatonics Ltd for £1.68 million.	Jan. 24	CI
SkinBioTherapeutics suffers acquisition delay but aims for early 2024	Dec. 29	AN

SkinBioTherapeutics plc is a United Kingdom-based life science company, which is focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Companyâs segments include UK, US, and EU. The Company's platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company is targeting five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. The Company's product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis. The Company is also focused on the application of SkinBiotix technology in the treatment of various classes of skin wounds.

Sector

Biotechnology & Medical Research

Calendar

2024-11-25 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SKINBIOTHERAPEUTICS PLC	-39.34%	22.21M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs